CNC Stock Analysis — Centene Corporation
Sector: Healthcare
AI Verdict
You’re paying a below-average multiple for a business with scale advantages, but the extreme RSI means any stumble could trigger a sharp correction.
Competitive Moat
Centene operates as a managed care organization specializing in government-sponsored healthcare programs like Medicaid and Medicare, giving it scale and regulatory expertise that smaller competitors struggle to match. Its deep relationships with state agencies and ability to navigate complex reimbursement structures create high barriers to entry.
Summary
RSI at 86.9 signals CNC is extremely overbought despite a -5.68% one-year return.
Where It Stands
Centene trades at 16.7x next year's earnings, below the healthcare sector median of 22x, but its RSI of 86.9 is flashing a severe overbought warning after a -5.68% annual return.
Key Metrics
- RSI: 86.9 — Overbought
- Forward P/E: 16.7x
- Revenue Growth: +0.2%
- Market Cap: $28.8B
- 1-Year Return: -5.68%
- 52-Week High: $62.21
- 52-Week Low: $25.08
Analyst Consensus
10 Buy · 15 Hold · 1 Sell (26 analysts)
Bull Case
Forward P/E of 16.7x is a discount to the sector median, while trailing revenue growth of 17.0% shows the business is still expanding.
Bear Case
With RSI at 86.9, even a modest pullback to neutral territory could erase several percentage points from the current level.
Catalyst to Watch
Watch for state Medicaid contract renewals or changes in reimbursement rates, as these directly impact Centene's margin outlook.